Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

NEW YORK – AstraZeneca and Daiichi Sankyo have begun treating high-risk non-small cell lung cancer patients with their TROP2-directed antibody drug conjugate Datroway (datopotamab deruxtecan) and ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

European stock markets closed mixed Friday as the Stoxx Europe 60 rose 0.11%, Germany's DAX 40 eased 0.07%, the FTSE 100 in London gained 0.31%, France's CAC 40 rose 0.11% and the Swiss Market Index ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...